Join the Iowa Biotechnology Association

The Iowa Biotechnology Association (IBA) was formed in 1994 to advance opportunities in Iowa for the improvement of the human environmental and economic well-being through the development and application of value-added technologies in the life sciences.

Working cooperatively, the members hope to enhance the ability to commercialize new technologies in a timely manner and reduce the lead time for deployment. Activities of the association are designed to give companies doing business in Iowa an edge in delivering timely new products to consumers through the sharing of ideas regarding the transfer and development of technologies.

Destination Iowa

This section will answer many of your questions regarding the life science industry in Iowa, the province's economy, tax structure and cost of living, education, transportation, climate, recreational opportunities, history, industry resources, and more.

Local News...

Free News Release Posting & Archiving Service


• The CYPHER(R) Stent outperforms the Taxus(R) Stent in people with diabetes  In patients with diabetes, the CYPHER(R) Sirolimus-eluting Coronary Stent outperformed the Taxus(R) Stent with lower rates of in-segment restenosis, target lesion revascularization and major adverse events at nine months according to clinical data.
  Johnson & Johnson  August 28, 2008  
  
  
• Monsanto and Evogene collaborate on yield and stress research  Monsanto Company and Evogene have entered into a five-year research and development collaboration focused on identifying key plant genes related to yield, environmental stress and fertilizer utilization.
  Monsanto Company  August 28, 2008  
  
  
• Amgen alters anemia drug discounts  Amgen is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product's safety.
  The New York Times  August 27, 2008  Andrew Pollack
  
  
• CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent receives CE Mark approval  Cordis Corporation announced that it has received CE mark approval to market the CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent for the treatment of acute myocardial infarction (AMI), more commonly known as a heart attack.
  Johnson & Johnson  August 27, 2008  
  
  
• Amylin Pharmaceuticals and Eli Lilly provide context for FDA alert for BYETTA  Amylin Pharmaceuticals and Eli Lilly and Company in a conference call provided context and additional information regarding the August 18, 2008 U.S. Food and Drug Administration (FDA) update to a prior alert for BYETTA(R) (exenatide) injection referencing pancreatitis.
  Amylin Pharmaceuticals, Inc.  August 26, 2008  
  
  

More... | Submit News Release | National News

New Job Postings...

Free Job Posting Trial Offer

• Quality Research Scientist Embria Health Sciences (IA)
• Post-Doc Fellow, Methods Development Allen Institute for Brain Science (WA)
• Director of Pharmacoeconimics Ikaria, Inc. (NJ)
• Senior Research Associate, Pharmacology Ikaria, Inc. (WA)
• Principal Scientist, Pharmacology Ikaria, Inc. (WA)

More... | Job Advertising... | About Job Postings...

New Facilities Available...

ATC clean room constructors...validation guaranteed!

• Charter Construction Lab Building -- Seattle, WA
• Icogenex Biotech Incubator -- Seattle, WA
• University of Iowa Oakdale Research Park Biotech Building -- Coralville, IA
• University of Iowa Oakdale Research Park BioVentures Center -- Coralville, IA

More... | Facility Advertising...

Upcoming Events...

Free Event Posting Service

• 08/28/2008: The Not so Subtle Art of Marketing YOU
• 09/03/2008: Governor's 2008 Economic and Workforce Development Conference
• 09/08/2008: 19th Annual LifeScience Alley Institute Scholarship Golf Tournament
• 09/08/2008: Northwest Medical Informatics Symposium
• 09/08/2008: Micro Nano Breakthrough Conference

More... | Submit Event | Event Advertising...